AVITA Therapeutics Forecast, price target & analysts
AVITA Therapeutics Target price 2025 - Analyst rating & recommendation
AVITA Therapeutics Classifications & Recommendation:
AVITA Therapeutics Price Target
| Target Price | $16.12 |
| Price | $9.02 |
| Potential |
78.76%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target AVITA Therapeutics 2026 .
The average AVITA Therapeutics target price is $16.12.
This is
78.76%
register free of charge
$23.93
165.30%
register free of charge
$10.18
12.87%
register free of charge
|
|
| A rating was issued by 9 analysts: 6 Analysts recommend AVITA Therapeutics to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AVITA Therapeutics stock has an average upside potential 2026 of
78.76%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 64.25 | 102.43 |
| 28.14% | 59.43% | |
| EBITDA Margin | -86.24% | -16.25% |
| 64.36% | 81.16% | |
| Net Margin | -98.02% | -67.74% |
| 33.22% | 30.89% |
9 Analysts have issued a sales forecast AVITA Therapeutics 2025 . The average AVITA Therapeutics sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an AVITA Therapeutics EBITDA forecast 2025. The average AVITA Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 AVITA Therapeutics Analysts have issued a net profit forecast 2025. The average AVITA Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.39 | -2.63 |
| 70.71% | 10.04% | |
| P/E | negative | |
| EV/Sales | 2.34 |
6 Analysts have issued a AVITA Therapeutics forecast for earnings per share. The average AVITA Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
AVITA Therapeutics...
Current AVITA Therapeutics Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Apr 10 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Apr 04 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
| Lake Street |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Apr 10 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Apr 04 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 18 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Feb 20 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Feb 14 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jan 08 2025 |
|
Locked
Lake Street:
Locked
➜
Locked
|
Jan 08 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
